$7.08
Pharming Group N.V. is a biotechnology business based in the US. Pharming Group N.V. shares (PHAR) are listed on the NASDAQ and all prices are listed in US Dollars. Pharming Group N.V. employs 382 staff and has a trailing 12-month revenue of around $277.6 million.
Our top picks for where to buy Pharming Group stock
How to buy Pharming Group N.V. stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PHAR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Pharming Group N.V. stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Pharming Group N.V. stock price (NASDAQ: PHAR)
Use our graph to track the performance of PHAR stocks over time.Pharming Group N.V. shares at a glance
Latest market close | $7.08 |
---|---|
52-week range | $6.65 - $16.71 |
50-day moving average | $8.04 |
200-day moving average | $10.19 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.19 |
Is it a good time to buy Pharming Group N.V. stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pharming Group N.V. price performance over time
Historical closes compared with the close of $7.08 from 2024-09-06
1 week (2024-08-30) | -7.93% |
---|---|
1 month (2024-08-07) | -10.38% |
3 months (2024-06-07) | -16.11% |
6 months (2024-03-07) | -36.79% |
1 year (2023-09-07) | -42.20% |
---|---|
2 years (2022-09-07) | -40.10% |
3 years (2021-09-03) | N/A |
5 years (2019-09-03) | N/A |
Pharming Group N.V. financials
Revenue TTM | $277.6 million |
---|---|
Gross profit TTM | $188.1 million |
Return on assets TTM | -1.74% |
Return on equity TTM | -6.33% |
Profit margin | -4.8% |
Book value | $0.33 |
Market Capitalization | $536.2 million |
TTM: trailing 12 months
Pharming Group N.V. share dividends
We're not expecting Pharming Group N.V. to pay a dividend over the next 12 months.
Pharming Group N.V. share price volatility
Over the last 12 months, Pharming Group N.V.'s shares have ranged in value from as little as $6.65 up to $16.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pharming Group N.V.'s is 0.842. This would suggest that Pharming Group N.V.'s shares are less volatile than average (for this exchange).
To put Pharming Group N.V.'s beta into context you can compare it against those of similar companies.
- Alexion Pharmaceuticals (ALXN.US): 1.2595
- Repligen Corporation (RGEN.US): 0.952
- Teva Pharma Industries Ltd ADR (TEVA.US): 0.901
Pharming Group N.V. overview
Pharming Group N. V. , a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.
Frequently asked questions
What percentage of Pharming Group N.V. is owned by institutions?Currently 0.077% of Pharming Group N.V. shares are held by institutions. How many people work for Pharming Group N.V.?
Latest data suggests 382 work at Pharming Group N.V.. When does the fiscal year end for Pharming Group N.V.?
Pharming Group N.V.'s fiscal year ends in December. Where is Pharming Group N.V. based?
Pharming Group N.V.'s address is: Darwinweg 24, Leiden, Netherlands, 2333 CR What is Pharming Group N.V.'s ISIN number?
Pharming Group N.V.'s international securities identification number is: US71716E1055
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question